📊 ATAI Key Takeaways
Is Atai Beckley N.V. (ATAI) a Good Investment?
AtaiBeckley is an early-stage pharmaceutical company with exceptional revenue growth (+1228% YoY) but from a near-zero base ($954K annually), paired with massive operating losses (-$30.9M) creating an unsustainable burn rate. While the balance sheet is strong with $43.1M cash, zero debt, and 10x liquidity ratios, current cash burn of $21.1M annually provides only ~2 years of runway before requiring additional financing or achieving profitability.
Atai Beckley N.V.'s fundamentals remain weak: revenue is minimal and declining, while operating and net losses are exceptionally large relative to sales. The balance sheet is currently supported by high liquidity and no long-term debt, but negative free cash flow and a cash balance below one year of recent operating burn raise meaningful funding-risk concerns unless the company materially improves commercialization or secures new capital.
Atai Beckley N.V. Key Strengths (ATAI)
- Exceptional revenue growth rate of 1227.6% year-over-year demonstrates early commercialization momentum
- Fortress balance sheet with $198.7M stockholders equity, zero long-term debt, and 10.02x current ratio providing significant financial flexibility
- Strong cash position of $43.1M with minimal leverage provides runway for development
- Debt-free balance sheet with no long-term debt reducing financial leverage risk
- Strong near-term liquidity ratios indicate current obligations are well covered
- Positive equity base and sizable total assets provide some balance-sheet flexibility
ATAI Stock Risks: Atai Beckley N.V. Investment Risks
- Unsustainable cash burn of $21.1M annually against minimal revenue of $954K results in negative operating margin of -3239%, indicating massive operating inefficiency
- Cash reserves of $43.1M at current burn rate provide only ~2 years of funding, requiring near-term achievement of profitability or significant additional capital raises
- Extreme losses with -$29.8M net income and -3121.8% net margin indicate fundamental business model challenges in pharmaceutical sector with uncertain path to profitability
- Limited revenue base creates execution risk; high growth rate from near-zero may not be sustainable
- Extreme negative operating and net margins show the business is far from self-sustaining
- Operating cash burn is heavy relative to cash on hand, implying limited runway without improvement or external funding
- Revenue base is very small and declined year over year, indicating weak growth quality and limited operating traction
Key Metrics to Watch
- Operating cash burn trajectory and cash runway extension
- Revenue growth sustainability and gross margin achievement
- Path to operating profitability and quarterly cash burn improvement
- Cash and equivalents relative to quarterly operating cash burn
- Revenue growth and operating loss trend
Atai Beckley N.V. (ATAI) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 10.02x current ratio provides a solid financial cushion.
ATAI Profit Margin, ROE & Profitability Analysis
ATAI vs Healthcare Sector: How Atai Beckley N.V. Compares
How Atai Beckley N.V. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Atai Beckley N.V. Stock Overvalued? ATAI Valuation Analysis 2026
Based on fundamental analysis, Atai Beckley N.V. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Atai Beckley N.V. Balance Sheet: ATAI Debt, Cash & Liquidity
ATAI Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Atai Beckley N.V.'s revenue has declined by 98% over the 5-year period, indicating business contraction. The most recent EPS of $-0.25 indicates the company is currently unprofitable.
ATAI Revenue Growth, EPS Growth & YoY Performance
ATAI Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $40.0K | -$26.3M | $-0.16 |
| Q2 2025 | $273.0K | -$27.7M | $-0.14 |
| Q1 2025 | N/A | -$26.4M | $-0.15 |
| Q3 2024 | $40.0K | -$21.9M | $-0.14 |
| Q2 2024 | $172.0K | -$33.0M | $-0.21 |
| Q1 2024 | N/A | -$26.7M | $-0.17 |
| Q3 2023 | $24.0K | -$21.9M | $-0.14 |
| Q2 2023 | $170.0K | -$33.0M | $-0.21 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Atai Beckley N.V. Dividends, Buybacks & Capital Allocation
ATAI SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Atai Beckley N.V. (CIK: 0001840904)
📋 Recent SEC Filings
❓ Frequently Asked Questions about ATAI
What is the AI rating for ATAI?
Atai Beckley N.V. (ATAI) has a Combined AI Grade of C from Claude (C) and ChatGPT (C) with 68% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are ATAI's key strengths?
Claude: Exceptional revenue growth rate of 1227.6% year-over-year demonstrates early commercialization momentum. Fortress balance sheet with $198.7M stockholders equity, zero long-term debt, and 10.02x current ratio providing significant financial flexibility. ChatGPT: Debt-free balance sheet with no long-term debt reducing financial leverage risk. Strong near-term liquidity ratios indicate current obligations are well covered.
What are the risks of investing in ATAI?
Claude: Unsustainable cash burn of $21.1M annually against minimal revenue of $954K results in negative operating margin of -3239%, indicating massive operating inefficiency. Cash reserves of $43.1M at current burn rate provide only ~2 years of funding, requiring near-term achievement of profitability or significant additional capital raises. ChatGPT: Extreme negative operating and net margins show the business is far from self-sustaining. Operating cash burn is heavy relative to cash on hand, implying limited runway without improvement or external funding.
What is ATAI's revenue and growth?
Atai Beckley N.V. reported revenue of $954.0K.
Does ATAI pay dividends?
Atai Beckley N.V. does not currently pay dividends.
Where can I find ATAI SEC filings?
Official SEC filings for Atai Beckley N.V. (CIK: 0001840904) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is ATAI's EPS?
Atai Beckley N.V. has a diluted EPS of $-0.08.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined grade reflects both perspectives for balanced insights.
What is ATAI's fundamental grade?
Based on our AI fundamental analysis in June 2026, Atai Beckley N.V. has a C grade with 68% confidence. Review the strengths and risks sections above for full context. This is not investment advice.
Is ATAI stock overvalued or undervalued?
Valuation metrics for ATAI: ROE of -15.0% (sector avg: 15%), net margin of -3,121.8% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
What is ATAI's AI grade for 2026?
Our dual AI analysis gives Atai Beckley N.V. a combined C grade for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is ATAI's free cash flow?
Atai Beckley N.V.'s operating cash flow is $-21.1M, with capital expenditures of $0.0. FCF margin is -2,210.7%.
How does ATAI compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -3,121.8% (avg: 12%), ROE -15.0% (avg: 15%), current ratio 10.02 (avg: 2).